top of page
O'Donnell joins Ariello VP team

Consultancy and provider of Regulatory Affairs, Pharmacovigilance and Auditing & QA solutions and services, Arriello ( appoints leading Pharmacovigilance expert Kieran O'Donnell as Vice President of Global Drug Safety.  Previously acting as Principal Consultant for Arriello, O’Donnell will further strengthen the company’s Pharmacovigilance capabilities and operations and comes as Arriello continues to experience soaring international demand for support with intensifying international Pharmacovigilance (PV) and Safety workloads.

“Arriello has huge global potential and that’s what really excites me.  The company is working with some really interesting clients, on a good mix of both established projects and some really cutting-edge engagements. That’s very enticing, along with Arriello’s real breadth and depth of PV services,” says Kieran O’Donnell.

“There’s an enormous amount to do, and Arriello is in an enviable position with quite a unique proposition.  It has the feel and client intimacy of a small company, yet with a large and global footprint.  I feel privileged to be joining at such an exciting and pivotal point in Arriello’s story.”

As an experienced expert in consulting on and developing PV systems; compliance and GVP; process improvement; and legislation and training, O’Donnell has worked in Drug Safety since 1999 – across both small and large pharmaceutical companies, as well as CROs.

His previous roles have included Vice President of Pharmacovigilance Services at TMC Pharma Services; Senior Consultant at Navitas; and Director of Pharmacovigilance at ORION Clinical Services where he oversaw Global Drug Safety services.  Here, Pharmacovigilance activities included all aspects of pre- and post-marketing pharmacovigilance and fulfilling the role of Qualified Person (and Deputy) for Pharmacovigilance.  O’Donnell has also held PV roles at Shire and i3 Drug Safety, during which time he honed his interest in Pharmacovigilance systems and quality.

As well as a master’s degree, Kieran holds a PgDip qualification in Pharmacovigilance and is a current member of the RQA PV Committee.

“We are incredibly excited to welcome Kieran to our senior team, and to have the opportunity to work with a PV professional at his level,” comments Alan White, CEO, Arriello.  “Kieran brings a breadth and degree of expertise that will see him take our already great systems and operations to the next level, introducing more advanced thinking and a greater emphasis on clinical work – which he will spearhead.   I see Kieran as a linchpin at a critical point in our company’s growth.  Bringing someone in at his level now will ensure we maintain our current momentum.”

Kieran’s arrival comes hot on the heels of Helen Lowe (, the company’s new Auditing & QA Director, who joined Arriello in June 2021.

bottom of page